Therefore, the aim of this study was to evaluate and compare the long-term effect of the GLP-1 RA semaglutide and the DPP-4 inhibitor sitagliptin on body weight and lipid metabolism in patients with T2DM after a 26- and 52-week follow-up. This evidence concerns the gene GCG and type 2 diabetes mellitus.